<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure - Emami, S - 2022 | Cochrane Library</title> <meta content="Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure - Emami, S - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012131.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure - Emami, S - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012131.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012131.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure" name="citation_title"/> <meta content="Sara Emami" name="citation_author"/> <meta content="Stein Eye Institute, UCLA" name="citation_author_institution"/> <meta content="Ken Kitayama" name="citation_author"/> <meta content="Stein Eye Institute, UCLA" name="citation_author_institution"/> <meta content="Anne L Coleman" name="citation_author"/> <meta content="Stein Eye Institute, UCLA" name="citation_author_institution"/> <meta content="coleman@jsei.ucla.edu" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD012131.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/06/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012131.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012131.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012131.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Bacterial Agents [therapeutic use]; Dexamethasone [therapeutic use]; *Endophthalmitis [drug therapy]; *Eye Diseases; *Retinal Detachment; Steroids [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012131.pub3&amp;doi=10.1002/14651858.CD012131.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012131\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012131\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012131.pub3",title:"Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure",firstPublishedDate:"Jun 6, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012131.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012131.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012131.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012131.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012131.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012131.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012131.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012131.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012131.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012131.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1353 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012131.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-sec-0076"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/appendices#CD012131-sec-0081"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/supinfo/CD012131StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/supinfo/CD012131StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/information#CD012131-cr-0004">Sara Emami</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/information#CD012131-cr-0005">Ken Kitayama</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012131.pub3/information#CD012131-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Anne L Coleman</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/information/en#CD012131-sec-0092">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 June 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012131.pub3">https://doi.org/10.1002/14651858.CD012131.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012131-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012131-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012131-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012131-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012131-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012131-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012131-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012131-abs-0001" lang="en"> <section id="CD012131-sec-0001"> <h3 class="title" id="CD012131-sec-0001">Background</h3> <p>Endophthalmitis refers to severe infection within the eye that involves the aqueous humor or vitreous humor, or both, and that threatens vision. Most cases of endophthalmitis are exogenous (i.e. due to inoculation of organisms from an outside source), and most exogenous endophthalmitis is acute and occurs after an intraocular procedure. The mainstay of treatment is emergent administration of broad‐spectrum intravitreous antibiotics. Due to their anti‐inflammatory effects, steroids in conjunction with antibiotics have been proposed as being beneficial in endophthalmitis management. </p> </section> <section id="CD012131-sec-0002"> <h3 class="title" id="CD012131-sec-0002">Objectives</h3> <p>To assess the effects of antibiotics combined with steroids versus antibiotics alone for the treatment of acute endophthalmitis following intraocular surgery or intravitreous injection. </p> </section> <section id="CD012131-sec-0003"> <h3 class="title" id="CD012131-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2021, Issue 8), MEDLINE Ovid (1946 to August 2021), Embase Ovid (1980 to August 2021), LILACS (Latin American and Caribbean Health Sciences Literature database) (1982 to August 2021), the ISRCTN registry; searched August 2021, ClinicalTrials.gov; searched August 2021, and the WHO International Clinical Trials Registry Platform; searched August 2021. We did not use any date or language restrictions in the electronic searches for trials. </p> </section> <section id="CD012131-sec-0004"> <h3 class="title" id="CD012131-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) comparing the effectiveness of adjunctive steroids with antibiotics alone in the management of acute, clinically diagnosed endophthalmitis following intraocular surgery or intravitreous injection. We excluded trials with participants with endogenous endophthalmitis unless outcomes were reported by source of infection. We imposed no restrictions on the method or order of administration, dose, frequency, or duration of antibiotics and steroids. </p> </section> <section id="CD012131-sec-0005"> <h3 class="title" id="CD012131-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodology, and graded the certainty of the body of evidence for six outcomes using the GRADE classification. </p> </section> <section id="CD012131-sec-0006"> <h3 class="title" id="CD012131-sec-0006">Main results</h3> <p>We included four RCTs with a total of 264 eyes of 264 participants in this review update. The studies were conducted in South Africa, India, and the Netherlands. All studies used intravitreous dexamethasone for adjunctive steroid therapy and a combination of two intravitreous antibiotics that provided gram‐positive and gram‐negative coverage for the antibiotic therapy. We judged two trials to be at overall low risk of bias, and the other two studies to be at overall unclear risk of bias due to lack of reporting of study methods. Only one study was registered in a clinical trial register.  </p> <p>While none of the included studies reported the primary outcome of complete resolution of endophthalmitis as defined in our protocol, one study reported combined anatomical and functional success (i.e. proportion of participants with intraocular pressure of at least 5 mmHg and visual acuity of at least 6/120). Very low certainty evidence suggested no difference in combined success when comparing adjunctive steroid to antibiotics alone (risk ratio (RR) 1.08, 95% confidence interval (CI) 0.80 to 1.45; 32 participants). Low certainty evidence from two studies suggested that adjunctive dexamethasone may result in having a good visual outcome (Snellen visual acuity 6/6 to 6/18) at 3 months compared with antibiotics alone (RR 1.95, 95% CI 1.05 to 3.60; 60 participants); however, the evidence was less conclusive at 12 months (RR 1.12, 95% CI 0.92 to 1.37; 2 studies; 195 participants; low certainty evidence). Investigators of one study reported improvement in visual acuity, but we could not estimate the effect of adjunctive steroid therapy because the study investigators did not provide any estimates of precision. Only one study examined intraocular pressure (IOP). The evidence suggests that adjunctive dexamethasone may reduce IOP slightly after 12 months of interventions (mean difference −1.90, 95% CI −3.78 to 0.07; 1 study; 167 participants; low certainty evidence). Three studies reported adverse events (retinal detachment, hypotony, proliferative vitreoretinopathy, seclusion of pupil, floaters, and pucker). The total numbers of adverse events were 14 out of 111 (12.6%) for those who received dexamethasone versus 12 out of 116 (10.3%) for those who did not. We could only perform a pooled analysis for the occurrence of retinal detachment: any difference between the two treatment groups was uncertain (RR 1.41, 95% CI 0.53 to 3.74; 227 participants; low certainty evidence). No study reported cost‐related outcomes. </p> </section> <section id="CD012131-sec-0007"> <h3 class="title" id="CD012131-sec-0007">Authors' conclusions</h3> <p>The currently available evidence on the effectiveness of adjunctive steroid therapy versus antibiotics alone in the management of acute endophthalmitis after intraocular surgery is inadequate. We found no studies that had enrolled cases of acute endophthalmitis following intravitreous injection. A combined analysis of two studies suggests that use of adjunctive steroids may provide a higher chance of having a good visual outcome at three months than not using adjunctive steroids. However, considering that most of the confidence intervals crossed the null, and that this review was limited in scope and applicability to clinical practice, it is not possible to conclude whether the use of adjunctive steroids is effective at this time. Any future trials should examine whether adjunctive steroids may be useful in certain clinical settings such as type of causative organism or etiology. These studies should include outcomes that take patients' symptoms and clinical examination into account; report outcomes in a uniform and consistent manner; and follow up at short‐ and long‐term intervals. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012131-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012131-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012131-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012131-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012131-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012131-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012131-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012131-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012131-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012131-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012131-abs-0002" lang="en"> <h3>Steroids plus antibiotics versus antibiotics alone for the treatment of acute endophthalmitis after eye surgery or injections into the eye </h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to find out whether using steroids in addition to antibiotics is more effective than using antibiotics alone for acute endophthalmitis (infection inside the eyeball that can cause vision loss) after eye surgery or injections into the eye. We looked for all studies that answered this question and found four studies. </p> <p><b>Key messages</b> </p> <p>It is uncertain whether using steroids in addition to antibiotics is helpful or harmful compared with using antibiotics alone to treat acute endophthalmitis after eye surgery or injections into the eye. </p> <p><b>What was studied in the review?</b> </p> <p>Endophthalmitis is rare, but it is important for people undergoing surgery or injections to the eye to be aware of the risk and for their doctors to know how best to treat it because it can result in vision loss. It is most commonly caused by entry of bacteria into the eye during, or a few days after, surgery or injection. As soon as endophthalmitis is suspected, a sample of the fluid inside the eye is usually obtained (and the fluid drained in severe cases), and antibiotics that cover most types of bacteria are injected into the eye. Although the use of antibiotics is widely accepted, the use of additional steroids to treat endophthalmitis is the subject of debate. Steroids may help to decrease the inflammation inside the eye in people with endophthalmitis. We looked at whether giving steroids in addition to antibiotics affects patient outcomes. </p> <p><b>What are the main results of the review?</b> </p> <p>We found four studies from South Africa, India, and the Netherlands. Almost all study participants had endophthalmitis after cataract surgery. All four studies compared injecting dexamethasone (a steroid) plus two antibiotics into the eye versus injecting only antibiotics into the eye. Low certainty evidence showed that more participants in the group receiving dexamethasone had a good visual outcome 3 months after treatment than in the antibiotics‐only group, but the evidence was uncertain at 12 months. The effects of using steroids on resolution of endophthalmitis and harms were also uncertain. Given the uncertainty of evidence for most outcomes, it is not clear whether doctors should use steroids with antibiotics to treat endophthalmitis after a procedure in the eye. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We searched for studies published up to 17 August 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012131-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012131-sec-0076"></div> <h3 class="title" id="CD012131-sec-0077">Implications for practice</h3> <section id="CD012131-sec-0077"> <p>Evidence for the effectiveness of steroids in conjunction with intravitreous antibiotics for the treatment of acute endophthalmitis following intraocular procedure is insufficient to provide support either for or against their usage. One trial indirectly measured treatment success by determining whether participants achieved improvements in visual acuity or intraocular pressure, but the effect of adjunctive steroid therapy on this outcome was uncertain. We found low certainty evidence suggesting there is a higher chance of having a good visual outcome at three months in the adjunctive steroid group compared with antibiotics alone, and no evidence of a difference between groups at 12 months. Furthermore, the effect of adjunctive steroids on the rate of complications (e.g. retinal detachment) remains unexplored. Although this review showed a possible beneficial effect on visual acuity with adjunctive steroid use, most of the current evidence on this topic is inconsistent and has major limitations. We therefore cannot conclude at this time if adjunctive steroid therapy is beneficial or harmful in the treatment of acute postprocedure endophthalmitis when compared to antibiotics alone.  </p> </section> <h3 class="title" id="CD012131-sec-0078">Implications for research</h3> <section id="CD012131-sec-0078"> <p>This review highlights the limited amount of randomized controlled trial (RCT) data available for assessing the effect of adjunctive steroids for postprocedure endophthalmitis treatment, as well as potential ways to expand the current literature. Most of the RCTs and comparative, non‐randomized studies that have been conducted to date have focused on treatment of endophthalmitis after cataract surgery. This is understandable considering that the large majority of endophthalmitis occurs after cataract surgery; however, we believe that studying the effect of adjunctive steroids on other intraocular surgeries, as well as intraocular injections, is also important. Furthermore, two of the four included studies combined patients of different etiologies (e.g. post‐traumatic) for some outcomes, which could make the patient population more heterogeneous than desired. Conducting such larger RCTs may also allow for examination of the effect of adjunctive steroid therapy by type of causative organism. Studying the comparison of adjunctive steroid therapy and antibiotics alone in more specific patient populations may not only help us understand whether steroids should be administered for endophthalmitis, but also for which cases of endophthalmitis. </p> <p>One of the major limitations of this review was inconsistency of the outcomes reported by the trials and the time intervals at which these outcomes were collected. Since the reporting of most outcomes differed across studies, few meta‐analyses were possible. Any future trials should therefore report outcomes in ways that facilitate comparing findings with previous research. We also believe that it is important to formulate an outcome that considers the patient's symptoms (e.g. pain, discharge) and clinical examination (e.g. inflammatory changes) to measure the success of a treatment option. Ideally, a standardized measure would be created and adopted by multiple trials. An example of such an outcome is the inflammation score in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>. Unfortunately, since <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> reported this outcome for postoperative and post‐traumatic patients as a whole, we decided not to include this outcome in the review. Any future studies should also have earlier (i.e. a month or earlier) and later (i.e. several years) follow‐up intervals to determine whether adjunctive steroid therapy is beneficial or harmful throughout the post‐treatment period.  </p> <p>To maximize the applicability of future trials, we recommend employing the treatment regimen that is considered standard practice with regard to the use of vitrectomy as well as antibiotic and steroid choice, dosage, and frequency. Also, researchers should conduct trials with sufficient power to detect important clinical differences and implement methods to minimize bias. This requires that researchers not only use methods that reduce the risk of bias (e.g. random sequence generation; allocation concealment; masking of participants, personnel, and outcome assessors; accounting for missing participants), but also report how they performed these methods. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012131-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012131-sec-0008"></div> <div class="table" id="CD012131-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Combined steroid and antibiotic therapy compared with antibiotics alone for acute endophthalmitis after intraocular procedure</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combined steroid and antibiotic therapy compared with antibiotics alone for acute endophthalmitis after intraocular procedure</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection) </p> <p><b>Settings:</b> ophthalmology clinic or hospital </p> <p><b>Intervention:</b> steroids plus antibiotics </p> <p><b>Comparison:</b> antibiotics alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes*</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks** (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>A<b>ntibiotics alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Combined steroid and antibiotic therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete resolution of endophthalmitis</b> </p> <p>at 3 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>813 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>878 per 1000</b><br/>(650 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b><br/>(0.80 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessed as combined anatomical and functional success, where anatomical success was defined as IOP of at least 5 mmHg, and functional success was defined as visual acuity of at least 6/120 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Visual acuity 6/6 to 6/18</b> </p> <p>at 3 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>585 per 1000</b><br/>(315 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.95</b><br/>(1.05 to 3.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Visual acuity 6/6 to 6/18, or LogMAR 0.3 or better</b> </p> <p>at 12 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>627 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>710 per 1000</b> </p> <p>(704 to 750)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b><br/>(0.92 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in visual acuity</b> </p> <p>at 3 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigators of 1 study reported improvement in visual acuity, but the effect of adjunctive steroid therapy could not be estimated because the study investigators did not provide standard deviations or standard errors. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intraocular pressure</b> </p> <p>at 12 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IOP was 15.8 mmHg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IOP was on average <b>1.90 lower</b> (95% CI −3.78 to 0.07). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>－</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167 <br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Low<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>at 3 to 12 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b><br/>(25 to 231) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.41</b><br/>(0.53 to 3.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data are for <b>retinal detachment</b>. Other reported adverse events included hypotony (2/29 participants), proliferative vitreoretinopathy (1/29 participants), seclusion of pupil (1/29 participants), floaters (3/167 participants), and pucker (5/167 participants). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Costs associated with the interventions</b> </p> <p>at 3 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The primary follow‐up time point for the review was 1 month; however, none of the included trials reported outcomes at this time point. Data are presented for the follow‐up time point for which data were available.<br/>**The basis for the <b>assumed risk</b> was the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded (−1) for unclear risk of bias in the trials.<br/><sup>2</sup>Downgraded (−1) for imprecision (wide confidence interval).<br/><sup>3</sup>Downgraded (−1) for indirectness of the outcome definition.<br/><sup>4</sup>Downgraded (−2) for imprecision (very wide confidence interval). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012131-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012131-sec-0009"></div> <section id="CD012131-sec-0010"> <h3 class="title" id="CD012131-sec-0010">Description of the condition</h3> <p>Endophthalmitis is a rare but potentially visually devastating condition that is defined as infection in the intraocular cavities (i.e. aqueous or vitreous humor, or both) (<a href="./references#CD012131-bbs2-0026" title="DurandML .Endophthalmitis. Clinical Microbiology and Infection2013;19(3):227-34.">Durand 2013</a>). A variety of pathogens, including bacteria, viruses, fungi, or parasites, can cause the infection; the culprit pathogens differ somewhat by the mechanism of infection (<a href="./references#CD012131-bbs2-0039" title="KeynanY , FinkelmanY , Lagace-WiensP .The microbiology of endophthalmitis: global trends and a local perspective. European Journal of Clinical Microbiology2012;31(11):2879-86.">Keynan 2012</a>). Most cases of endophthalmitis are exogenous; possible routes of infection include surgery, intravitreous injection, trauma, corneal infection, and glaucoma‐filtering bleb infection (<a href="./references#CD012131-bbs2-0056" title="SadakaA , DurandML , GilmoreMS .Bacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infection. Progress in Retinal and Eye Research2012;31(4):316-31.">Sadaka 2012</a>). Postoperative endophthalmitis is the most common type of exogenous endophthalmitis (<a href="./references#CD012131-bbs2-0039" title="KeynanY , FinkelmanY , Lagace-WiensP .The microbiology of endophthalmitis: global trends and a local perspective. European Journal of Clinical Microbiology2012;31(11):2879-86.">Keynan 2012</a>). While endophthalmitis is a possible complication of any intraocular surgery, 90% of postoperative endophthalmitis is due to cataract surgery, as it is the most frequent intraocular surgery (<a href="./references#CD012131-bbs2-0043" title="LemleyCA , HanDP .Endophthalmitis: a review of current evaluation and management. Retina2007;27(6):662-80.">Lemley 2007</a>). Endogenous endophthalmitis, which makes up 2% to 15% of endophthalmitis cases, occurs when organisms spread hematogenously from a distant infection site to the eye (<a href="./references#CD012131-bbs2-0039" title="KeynanY , FinkelmanY , Lagace-WiensP .The microbiology of endophthalmitis: global trends and a local perspective. European Journal of Clinical Microbiology2012;31(11):2879-86.">Keynan 2012</a>). The most common primary sites of infection are the liver, lung, and endocardium (<a href="./references#CD012131-bbs2-0037" title="JacksonTL , ParaskevopoulosT , GeorgalasI .Systematic review of 342 cases of endogenous bacterial endophthalmitis. Survey of Ophthalmology2014;59(6):627-35.">Jackson 2014</a>). </p> <section id="CD012131-sec-0011"> <h4 class="title">Epidemiology</h4> <p>The reported incidence of postoperative endophthalmitis varies widely, but available data indicate that the rate of endophthalmitis has been very low in recent years. Analyses of Medicare claims data in the USA showed that while the annual rate of post‐cataract surgery endophthalmitis increased from 1.79 (95% confidence interval (CI) 1.46 to 2.18) to 2.62 (95% CI 2.22 to 3.07) cases per thousand surgeries between 1994 and 2000 (<a href="./references#CD012131-bbs2-0061" title="WestES , BehrensA , McDonnellPJ , TielschJM , ScheinOD .The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology2005;112(8):1388-94.">West 2005</a>), it decreased from 1.32 (95% CI 1.27 to 1.38) to 1.11 (95% CI 1.06 to 1.16) per thousand surgeries between 2003 and 2004 (<a href="./references#CD012131-bbs2-0038" title="KeayL , GowerEW , CassardSD , TielschJM , ScheinOD .Postcataract surgery endophthalmitis in the United States: analysis of the complete 2003 to 2004 Medicare database of cataract surgeries. Ophthalmology2012;119(5):914-22.">Keay 2012</a>), and was stable between 2006 and 2011 (<a href="./references#CD012131-bbs2-0025" title="DuDT , WagonerA , BaroneSB , ZindermanCE , KelmanJA , MacurdyTE , et al.Incidence of endophthalmitis after corneal transplant or cataract surgery in a Medicare population. Ophthalmology2014;121(1):290-8.">Du 2014</a>). More recently, the Intelligent Research in Sight Registry found that the rate of endophthalmitis after cataract surgery was 0.08% (0.8 per 1000 surgeries) for 2013 and 2014 combined (<a href="./references#CD012131-bbs2-0022" title="ColemanAL .How big data informs us about cataract surgery: the LXXII Edward Jackson Memorial Lecture. American Journal of Ophthalmology2015;160(6):1091-103.">Coleman 2015</a>). Also, there were no cases of endophthalmitis following 21,501 office‐based cataract surgeries performed at Kaiser Permanente Colorado from 2011 to 2014 (<a href="./references#CD012131-bbs2-0035" title="IanchulevT , LitoffD , EllingerD , StiversonK , PackerM .Office-based cataract surgery: population health outcomes study of more than 21,000 cases in the United States. Ophthalmology2016;123(4):723-8.">Ianchulev 2016</a>). Reported incidences for other types of exogenous endophthalmitis are between 0.006% and 0.16% for intravitreous injection, between 0.3% and 0.7% for trabeculectomy, 2.0% for glaucoma drainage surgery, and between 0.9% and 17% for traumatic injury to the globe (<a href="./references#CD012131-bbs2-0056" title="SadakaA , DurandML , GilmoreMS .Bacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infection. Progress in Retinal and Eye Research2012;31(4):316-31.">Sadaka 2012</a>; <a href="./references#CD012131-bbs2-0060" title="SteinJD , Ruiz D Jr, BelskyD , LeePP , SloanFA .Longitudinal rates of postoperative adverse outcomes after glaucoma surgery among Medicare beneficiaries 1994 to 2005. Ophthalmology2008;115(7):1109-16.">Stein 2008</a>). </p> <p>Risk factors for exogenous endophthalmitis include host factors and factors associated with the procedure. Some preoperative risk factors are male gender, older age, black and Native American race, immunocompromized states (e.g. diabetes, chronic steroid use), and recent history of periocular infections (e.g. blepharitis, conjunctivitis) (<a href="./references#CD012131-bbs2-0033" title="HatchWV , CernatG , WongD , DevenyiR , BellCM .Risk factors for acute endophthalmitis after cataract surgery: a population-based study. Ophthalmology2009;116(3):425-30.">Hatch 2009</a>; <a href="./references#CD012131-bbs2-0038" title="KeayL , GowerEW , CassardSD , TielschJM , ScheinOD .Postcataract surgery endophthalmitis in the United States: analysis of the complete 2003 to 2004 Medicare database of cataract surgeries. Ophthalmology2012;119(5):914-22.">Keay 2012</a>; <a href="./references#CD012131-bbs2-0039" title="KeynanY , FinkelmanY , Lagace-WiensP .The microbiology of endophthalmitis: global trends and a local perspective. European Journal of Clinical Microbiology2012;31(11):2879-86.">Keynan 2012</a>). The main intraoperative risk factor is increased intraocular exposure to the patient’s adnexal and ocular surface flora, which increases with surgical complexity and complications such as posterior capsule rupture and vitreous loss (<a href="./references#CD012131-bbs2-0033" title="HatchWV , CernatG , WongD , DevenyiR , BellCM .Risk factors for acute endophthalmitis after cataract surgery: a population-based study. Ophthalmology2009;116(3):425-30.">Hatch 2009</a>; <a href="./references#CD012131-bbs2-0046" title="MamalisN , KearsleyL , BrintonE .Postoperative endophthalmitis. Current Opinion in Ophthalmology2002;13(1):14-8.">Mamalis 2002</a>). Possible reasons for the decline in the early 2000s therefore include improved surgical techniques, sterility, and prophylactic antibiotics (<a href="./references#CD012131-bbs2-0017" title="BarryP , CordovésL , GardnerS .ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. www.escrs.org/downloads/Endophthalmitis-Guidelines.pdf (accessed 23 February 2016).">Barry 2013</a>). A multicenter study across nine European countries showed that the use of antibiotic prophylaxis with intracameral cefuroxime at the end of cataract surgery decreased the rate of endophthalmitis from 0.35% to 0.05% (<a href="./references#CD012131-bbs2-0028" title="Endophthalmitis Study Group, European Society of Cataract and Refractive Surgeons.Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. Journal of Cataract and Refractive Surgery2007;33(6):978-88.">ESCRS Study 2007</a>). Higher rates of endophthalmitis are also associated with surgeries performed by surgeons with lower annual volume and fewer years of experience (<a href="./references#CD012131-bbs2-0038" title="KeayL , GowerEW , CassardSD , TielschJM , ScheinOD .Postcataract surgery endophthalmitis in the United States: analysis of the complete 2003 to 2004 Medicare database of cataract surgeries. Ophthalmology2012;119(5):914-22.">Keay 2012</a>). </p> </section> <section id="CD012131-sec-0012"> <h4 class="title">Clinical presentation and diagnosis</h4> <p>Postoperative endophthalmitis usually presents within one to two weeks after surgery (acute type), but can also present a few weeks or months after surgery (chronic type) (<a href="./references#CD012131-bbs2-0039" title="KeynanY , FinkelmanY , Lagace-WiensP .The microbiology of endophthalmitis: global trends and a local perspective. European Journal of Clinical Microbiology2012;31(11):2879-86.">Keynan 2012</a>). On average, endophthalmitis presents five days after intravitreous injection (<a href="./references#CD012131-bbs2-0044" title="LyallDM , TeyA , FootB , RoxburghST , VirdiM , RobertsonC , et al.Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye2012;26(12):1517-26.">Lyall 2012</a>; <a href="./references#CD012131-bbs2-0058" title="SimunovicMP , RushRB , HunyorAP , ChangAA .Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. British Journal of Ophthalmology2012;96(6):862-6.">Simunovic 2012</a>). While endogenous endophthalmitis occasionally affects both eyes, exogenous endophthalmitis affects only the eye that was exposed to the insult (<a href="./references#CD012131-bbs2-0036" title="JacksonTL , EykynSJ , GrahamEM , StanfordMR .Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. Survey of Ophthalmology2003;48(4):403-23.">Jackson 2003</a>; <a href="./references#CD012131-bbs2-0039" title="KeynanY , FinkelmanY , Lagace-WiensP .The microbiology of endophthalmitis: global trends and a local perspective. European Journal of Clinical Microbiology2012;31(11):2879-86.">Keynan 2012</a>). The most common symptoms, regardless of the mechanism, are eye pain, red eye, and decreased vision. People with exogenous endophthalmitis usually feel well otherwise and are afebrile (<a href="./references#CD012131-bbs2-0026" title="DurandML .Endophthalmitis. Clinical Microbiology and Infection2013;19(3):227-34.">Durand 2013</a>). On physical examination, endophthalmitis presents with eyelid and conjunctival swelling, injected conjunctiva, corneal edema, and poor view of the fundus due to inflammation in the aqueous or vitreous humor, or both (<a href="./references#CD012131-bbs2-0026" title="DurandML .Endophthalmitis. Clinical Microbiology and Infection2013;19(3):227-34.">Durand 2013</a>; <a href="./references#CD012131-bbs2-0039" title="KeynanY , FinkelmanY , Lagace-WiensP .The microbiology of endophthalmitis: global trends and a local perspective. European Journal of Clinical Microbiology2012;31(11):2879-86.">Keynan 2012</a>). Hypopyon, the accumulation of white blood cells in the anterior chamber, is found in over 80% of cases (<a href="./references#CD012131-bbs2-0042" title="LalwaniGA , Flynn HW Jr, ScottIU , QuinnCM , BerrocalAM , DavisJL , et al.Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology2008;115(3):473-6.">Lalwani 2008</a>). </p> <p>The main concern following endophthalmitis is persistent vision loss despite treatment. Visual outcome is highly dependent on the causative organism, with any streptococci causing the worst outcomes, and coagulase‐negative staphylococci causing milder cases (<a href="./references#CD012131-bbs2-0026" title="DurandML .Endophthalmitis. Clinical Microbiology and Infection2013;19(3):227-34.">Durand 2013</a>). Overall, approximately half of eyes affected by postcataract endophthalmitis do not regain a visual acuity of 20/40 or better, and 10% will lose useful vision (5/200 or worse) (<a href="./references#CD012131-bbs2-0029" title="Endophthalmitis Vitrectomy Study Group.Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Archives of Ophthalmology1995;113(12):1479-96.">EVS Group 1995</a>). As streptococci cause a higher rate of postinjection endophthalmitis than postcataract endophthalmitis, postinjection endophthalmitis is associated with poorer visual outcomes (<a href="./references#CD012131-bbs2-0058" title="SimunovicMP , RushRB , HunyorAP , ChangAA .Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. British Journal of Ophthalmology2012;96(6):862-6.">Simunovic 2012</a>). </p> <p>The diagnosis of endophthalmitis is made clinically, but is confirmed by a positive aqueous or vitreous culture. A vitreous specimen is preferable because it has a higher detection rate than an aqueous specimen (54.9% versus 22.5%) (<a href="./references#CD012131-bbs2-0018" title="BarzaM , PavanPR , DoftBH , WisniewskiSR , WilsonLA , HanDP , et al.Evaluation of microbiological diagnostic techniques in postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. Archives of Ophthalmology1997;115(9):1142-50.">Barza 1997</a>). Nevertheless, a negative culture, which occurs in about 30% of cases, does not exclude the diagnosis (<a href="./references#CD012131-bbs2-0026" title="DurandML .Endophthalmitis. Clinical Microbiology and Infection2013;19(3):227-34.">Durand 2013</a>). </p> <p>Specimen collection is performed by either needle aspirate (an office procedure) or by vitrectomy (performed in the operating room) (<a href="./references#CD012131-bbs2-0026" title="DurandML .Endophthalmitis. Clinical Microbiology and Infection2013;19(3):227-34.">Durand 2013</a>). Vitrectomy is considered a useful diagnostic as well as therapeutic method, as it is the fastest way of removing an infection from the vitreous humor. It is favored in patients with severe vision loss (i.e. worse than hand motion) and rapidly worsening vision, or those whose endophthalmitis is likely to be caused by more virulent strains (<a href="./references#CD012131-bbs2-0018" title="BarzaM , PavanPR , DoftBH , WisniewskiSR , WilsonLA , HanDP , et al.Evaluation of microbiological diagnostic techniques in postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. Archives of Ophthalmology1997;115(9):1142-50.">Barza 1997</a>; <a href="./references#CD012131-bbs2-0026" title="DurandML .Endophthalmitis. Clinical Microbiology and Infection2013;19(3):227-34.">Durand 2013</a>). </p> </section> </section> <section id="CD012131-sec-0013"> <h3 class="title" id="CD012131-sec-0013">Description of the intervention</h3> <p>Following specimen collection, endophthalmitis is immediately treated with antibiotics. Intravitreous administration of antibiotics is recommended, as other routes (e.g. topical, subconjunctival, intravenous) have been shown to be less effective (<a href="./references#CD012131-bbs2-0026" title="DurandML .Endophthalmitis. Clinical Microbiology and Infection2013;19(3):227-34.">Durand 2013</a>; <a href="./references#CD012131-bbs2-0050" title="PackerM , ChangDF , DeweySH , LittleBC , MamalisN , OettingTA , et al.Prevention, diagnosis, and management of acute postoperative bacterial endophthalmitis. Journal of Cataract and Refractive Surgery2011;37(9):1699-714.">Packer 2011</a>). While the antibiotic regimen ideally targets the antibiotic sensitivities of the causative organism, it may not be possible to distinguish between different organisms from the presenting symptoms and signs alone. Broad‐spectrum antibiotics (i.e. vancomycin plus ceftazidime or amikacin) are therefore typically used first. If there is no improvement in 48 hours, the culture results dictate whether to give the patient another injection of vancomycin or ceftazidime (<a href="./references#CD012131-bbs2-0026" title="DurandML .Endophthalmitis. Clinical Microbiology and Infection2013;19(3):227-34.">Durand 2013</a>). </p> <p>The use of steroids as adjunctive therapy for endophthalmitis remains controversial. The most commonly used and widely studied steroid is dexamethasone (<a href="./references#CD012131-bbs2-0019" title="BuiDK , CarvounisPE .Evidence for and against intravitreous corticosteroids in addition to intravitreous antibiotics for acute endophthalmitis. International Ophthalmology Clinics2014;54(2):215-24.">Bui 2014</a>). </p> </section> <section id="CD012131-sec-0014"> <h3 class="title" id="CD012131-sec-0014">How the intervention might work</h3> <p>Gram‐positive bacteria cause the vast majority of cases of postoperative and postinjection endophthalmitis. Most of these cases are caused by coagulase‐negative staphylococci, which are commonly found in the normal flora of the ocular surface (<a href="./references#CD012131-bbs2-0020" title="CalleganMC , EngelbertM , ParkeDW , JettBD , GilmoreMS .Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clinical Microbiology Reviews2002;15(1):111-24.">Callegan 2002</a>; <a href="./references#CD012131-bbs2-0039" title="KeynanY , FinkelmanY , Lagace-WiensP .The microbiology of endophthalmitis: global trends and a local perspective. European Journal of Clinical Microbiology2012;31(11):2879-86.">Keynan 2012</a>). All gram‐positive pathogens, except vancomycin‐resistant <i>Enterococcus</i>, are susceptible to vancomycin. Most gram‐negative pathogens that are responsible for bacterial endophthalmitis can be treated with an oxyimino‐cephalosporin (e.g. ceftazidime) or an aminoglycoside (e.g. amikacin) (<a href="./references#CD012131-bbs2-0032" title="HanDP , WisniewskiSR , WilsonLA , BarzaM , VineAK , DoftBH , et al.Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. American Journal of Ophthalmology1996;122(1):1-17.">Han 1996</a>; <a href="./references#CD012131-bbs2-0041" title="KunimotoDY , DasT , SharmaS , JalaliS , MajjiAB , GopinathanU , et al.Microbiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis. Endophthalmitis Research Group. American Journal of Ophthalmology1999;128(2):240-2.">Kunimoto 1999</a>). These antibiotics are bacteriocidal (i.e. they destroy bacteria directly), in contrast to bacteriostatic antibiotics, which work by inhibiting bacterial growth and replication. </p> <p>It has been hypothesized that steroids may be beneficial in the treatment of endophthalmitis due to their anti‐inflammatory effect. Experimental studies suggest that intraocular inflammation is incited by the growth of organisms and the antibiotic‐induced release of bacterial cell walls and cell wall components. While an inflammatory response is crucial to the clearance of the infecting organism, this response may result in irreversible damage of the sensitive photoreceptor cells and other secondary damage (<a href="./references#CD012131-bbs2-0020" title="CalleganMC , EngelbertM , ParkeDW , JettBD , GilmoreMS .Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clinical Microbiology Reviews2002;15(1):111-24.">Callegan 2002</a>; <a href="./references#CD012131-bbs2-0021" title="CalleganMC , GilmoreMS , Parke DW Jr.Chapter 48: The pathogenesis of infectious endophthalmitis. In: Duane's Foundations of Clinical Ophthalmology. CD-ROM edition. Vol. 2. Lippincott Williams &amp; Wilkins, 2006.">Callegan 2006</a>). Steroids decrease inflammation by inhibiting migration of macrophages, disruption of vascular membranes, and production of inflammatory mediators (<a href="./references#CD012131-bbs2-0056" title="SadakaA , DurandML , GilmoreMS .Bacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infection. Progress in Retinal and Eye Research2012;31(4):316-31.">Sadaka 2012</a>). In a rat model of endophthalmitis, a higher level of expression of inflammatory mediators tumor necrosis factor alpha (TNF‐α), interleukin 1 beta (IL‐1β), and interferon gamma (IFN‐γ) was associated with worse clinical presentation (<a href="./references#CD012131-bbs2-0051" title="PetropoulosIK , VantzouCV , LamariFN , KaramanosNK , AnastassiouED , PharmakakisNM .Expression of TNF-alpha, IL-1beta, and IFN-gamma in Staphylococcus epidermidis slime-positive experimental endophthalmitis is closely related to clinical inflammatory scores. Graefe's Archive for Clinical and Experimental Ophthalmology2006;244(10):1322-8.">Petropoulos 2006</a>). Targeting both the infection and subsequent inflammatory response could have synergistic effects and lead to more rapid resolution of endophthalmitis and improvement in vision. </p> <p>One argument against using steroids as adjunctive therapy is that they may worsen infection control, especially with fungal infections, due to the immunosuppressive properties of steroids. However, a retrospective review of 20 people with postcataract or post‐traumatic fungal endophthalmitis showed no difference in the visual outcomes of those who received intravitreous dexamethasone versus those who did not (<a href="./references#CD012131-bbs2-0045" title="MajjiAB , JalaliS , DasT , GopinathanU .Role of intravitreal dexamethasone in exogenous fungal endophthalmitis. Eye1999;13(Pt 5):660-5.">Majji 1999</a>). Furthermore, there was no statistically significant difference in mean vitreous vancomycin concentration among people with presumed postoperative bacterial endophthalmitis who were treated with versus without intravitreous dexamethasone (<a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>). </p> </section> <section id="CD012131-sec-0015"> <h3 class="title" id="CD012131-sec-0015">Why it is important to do this review</h3> <p>Although endophthalmitis is a rare complication of intraocular surgery and intravitreous injection, its treatment is an important clinical issue due to the large number of people who undergo these procedures and the poor visual outcomes after endophthalmitis. Antibiotics are well established as the mainstay of treatment, but the role of steroids remains unclear. Most literature on the use of steroids as adjunctive therapy are reports of preclinical or retrospective case studies; randomized controlled studies on this topic tend to have small sample sizes. By consolidating results across multiple studies in this review, we aimed to determine whether combination therapy with antibiotics and steroids has an obvious benefit over monotherapy with antibiotics. We also planned to address the question of whether there are certain clinical settings in which adjunctive therapy with steroids may be particularly useful in treating endophthalmitis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012131-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012131-sec-0016"></div> <p>To assess the effects of antibiotics combined with steroids versus antibiotics alone for the treatment of acute endophthalmitis following intraocular surgery or intravitreous injection. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012131-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012131-sec-0017"></div> <section id="CD012131-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012131-sec-0019"> <h4 class="title">Types of studies</h4> <p>We conducted this review according to our published Cochrane protocol (<a href="./references#CD012131-bbs2-0062" title="KimCH , ChenMF , ColemanAL .Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure. Cochrane Database of Systematic Reviews2016, Issue 3. Art. No: CD012131. [DOI: 10.1002/14651858.CD012131]">Kim 2016</a>). We included randomized controlled trials (RCTs) in our primary analyses.  </p> </section> <section id="CD012131-sec-0020"> <h4 class="title">Types of participants</h4> <p>We included trials with participants who had clinically diagnosed endophthalmitis within three months of undergoing any intraocular surgery or intravitreous injection (acute endophthalmitis). There was no restriction regarding the result of the vitreous or aqueous culture. We excluded trials with participants with endogenous endophthalmitis, unless outcomes were reported separately by source of infection. </p> </section> <section id="CD012131-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We included trials that compared antibiotics and steroids versus antibiotics alone for the management of acute postprocedure endophthalmitis. There was no restriction on the method of administration, dose, frequency, or duration of antibiotics or steroids. In participants who received both antibiotics and steroids, the two treatments could have been administered simultaneously, or one type of treatment could have been administered before the other treatment. </p> </section> <section id="CD012131-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD012131-sec-0023"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome of the review was complete resolution of endophthalmitis one month after the initiation of therapy. We considered complete resolution as resolution of associated symptoms or hypopyon, or both, but we also accepted definitions used by the investigators of the included trials. We based our primary analysis on one‐month outcomes to evaluate whether using steroids as adjunctive therapy provides any benefit in the short term. We also compared outcomes at three, six, and 12 months whenever data were available. </p> </section> <section id="CD012131-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012131-list-0001"> <li> <p>Proportion with best‐corrected visual acuity (BCVA) 20/40 (LogMAR 0.30) or better one month after the initiation of therapy. </p> </li> <li> <p>Improvement in BCVA, defined as a proportion with a gain of 2 lines or more from baseline on a LogMAR chart or equivalent, at one month. </p> </li> <li> <p>Mean change in intraocular pressure (IOP) from baseline at one month. When the mean one‐month change in IOP was not reported, we used the mean IOP at one month, as long as the baseline IOP was similar between intervention groups. </p> </li> <li> <p>Proportion with IOP less than 21 mmHg at one month.</p> </li> </ol> </p> <section id="CD012131-sec-0025"> <h6 class="title">Adverse events</h6> <p>We evaluated ocular and systemic adverse effects relating to antibiotic or steroid use that were reported in the included trials. </p> </section> <section id="CD012131-sec-0026"> <h6 class="title">Economic data</h6> <p>We did not conduct formal cost‐effectiveness analyses, but we compared the costs associated with the interventions when data were available. </p> </section> </section> </section> </section> <section id="CD012131-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012131-sec-0028"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following databases. There were no study design, language, or publication year restrictions. The date of the search was 17 August 2021. </p> <p> <ul id="CD012131-list-0002"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 8) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched August 2021) (<a href="./appendices#CD012131-sec-0082">Appendix 1</a>) </p> </li> <li> <p>MEDLINE Ovid (1946 to August 2021) (<a href="./appendices#CD012131-sec-0083">Appendix 2</a>) </p> </li> <li> <p>Embase Ovid (1980 to August 2021) (<a href="./appendices#CD012131-sec-0084">Appendix 3</a>) </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database (1982 to August 2021) (<a href="./appendices#CD012131-sec-0085">Appendix 4</a>) </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched August 2021) (<a href="./appendices#CD012131-sec-0086">Appendix 5</a>) </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched August 2021) (<a href="./appendices#CD012131-sec-0087">Appendix 6</a>) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched August 2021) (<a href="./appendices#CD012131-sec-0088">Appendix 7</a>) </p> </li> </ul> </p> </section> <section id="CD012131-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of included trials to identify additional relevant trials. We did not search conference proceedings for the specific purposes of this review because they are searched annually by Cochrane Eyes and Vision, and all reports from trials identified are included in CENTRAL. </p> </section> </section> <section id="CD012131-sec-0030"> <h3 class="title" id="CD012131-sec-0030">Data collection and analysis</h3> <section id="CD012131-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SE, KK) independently assessed the titles and abstracts of all records identified by the literature searches. We categorized each record as 'definitely relevant,' 'possibly relevant,' or 'definitely not relevant.' For records assessed as 'definitely relevant' or 'possibly relevant,' we obtained the full‐text report and grouped them into studies. Two review authors independently reviewed each study and classified each study as 'include,' 'exclude,' or 'unsure.' Any discrepancies between review authors were resolved by discussion at each stage of selection. We documented studies that were excluded following review of the full‐text reports, along with their reasons for exclusion, in the <a href="./references#CD012131-sec-0099" title="">Characteristics of excluded studies</a> table. For studies assessed as ‘unsure’ after review of the full‐text reports, we contacted the study authors for clarification. In cases where we received no response after two weeks, we classified the study based on available information. </p> </section> <section id="CD012131-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>We extracted and recorded data‐related study methods, participant characteristics, and outcomes from the selected trials onto standard paper data collection forms. We pilot‐tested the forms on one study before using them for all of the included studies. </p> <p>Two review authors (SE, KK) independently extracted the data, resolving any discrepancies by discussion. One review author entered the data into RevMan Web (<a href="./references#CD012131-bbs2-0054" title="Review Manager Web (RevMan Web).Version 4.4.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>), and a second review author checked the data entry. </p> </section> <section id="CD012131-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SE, KK) independently assessed the risk of bias of each included study according to Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012131-bbs2-0034" title="HigginsJP , AltmanDG , SterneJAC , editor(s).Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). We considered the following risk of bias domains. </p> <p> <ul id="CD012131-list-0003"> <li> <p>Selection bias: random sequence generation, allocation concealment before randomization</p> </li> <li> <p>Performance bias: masking of study participants and personnel</p> </li> <li> <p>Detection bias: masking of outcome assessors</p> </li> <li> <p>Attrition bias: loss to follow‐up</p> </li> <li> <p>Reporting bias: selective outcome reporting</p> </li> <li> <p>Other potential sources of bias (e.g. funding source, sponsor's involvement in trial)</p> </li> </ul> </p> <p>We evaluated each domain for each trial as low, high, or unclear risk. Any discrepancies between review authors were resolved by discussion. </p> </section> <section id="CD012131-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We measured treatment effects based on the types of data as described in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012131-bbs2-0023" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s), on behalf of the Cochrane Statistical Methods Group.Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>), which included the following. </p> <section id="CD012131-sec-0035"> <h5 class="title">Dichotomous data</h5> <p>We reported the proportions of participants with complete resolution of endophthalmitis, improvement of BCVA, IOP less than 21 mmHg, and adverse effects. We calculated risk ratios (RRs) with 95% CIs to estimate treatment effects. </p> </section> <section id="CD012131-sec-0036"> <h5 class="title">Continuous data</h5> <p>Outcomes with continuous data included mean IOP and mean change in IOP. We calculated mean differences with 95% CIs to estimate treatment effects. </p> </section> <section id="CD012131-sec-0037"> <h5 class="title">Qualitative data</h5> <p>We described types of adverse effects and economic data qualitatively whenever quantitative description was not possible. </p> </section> </section> <section id="CD012131-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The individual (one study eye per participant) was the unit of analysis. There were no unit of analysis issues because each person was randomized to a treatment, and only one eye was affected. </p> </section> <section id="CD012131-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study investigators to request unpublished data, clarify unclearly reported data, and/or provide reasons for missing data or loss to follow‐up. When we did not receive a response within two weeks, we used the information available in the published reports. We did not impute data for the purposes of this review. When we were unable to assume data were missing at random, we documented the outcomes with missing data and commented on potential implications in the <a href="#CD012131-sec-0070">Discussion</a> section of the review. We referred to Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for guidelines on how to interpret missing data (<a href="./references#CD012131-bbs2-0034" title="HigginsJP , AltmanDG , SterneJAC , editor(s).Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). </p> </section> <section id="CD012131-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity by examining variations in study characteristics (e.g. methodology, participant characteristics, interventions compared, follow‐up duration). We used the I<sup>2</sup> statistic to assess the degree of statistical heterogeneity across studies. When the I<sup>2</sup> statistic was greater than 50%, we considered the impact of heterogeneity to be substantial. We also performed a visual assessment of the forest plot to assess heterogeneity, with poor overlap of study estimates and CIs indicating heterogeneity. </p> </section> <section id="CD012131-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>Had we included 10 or more studies in a meta‐analysis, we would have created funnel plots in RevMan Web to assess publication bias. We evaluated selective outcome reporting as part of the risk of bias assessment. We planned to compare outcomes reported in the included studies with outcomes reported in the study protocols, published design and methods papers, or clinical trial registry records, when these were available. </p> </section> <section id="CD012131-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We presented the results in a narrative summary when there was substantial clinical or methodological heterogeneity, or when statistical heterogeneity and assessment of the forest plots indicated that meta‐analysis was not appropriate. In the absence of substantial heterogeneity, we combined the results of included studies and estimated treatment effects using meta‐analysis with a random‐effects model, or with a fixed‐effect model when the outcome was available from fewer than three studies. </p> </section> <section id="CD012131-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analysis and investigate heterogeneity by type of intraocular procedure (e.g. cataract, glaucoma, retina), mode of steroid delivery, mode of antibiotic delivery, class of antibiotic used, and use of pars plana vitrectomy, when sufficient data were available. </p> </section> <section id="CD012131-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to evaluate the impact of excluding studies at high risk of bias in one or more domains, studies with only unpublished outcome data, and industry‐funded studies, when sufficient data were available. </p> </section> <section id="CD012131-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>A summary of findings table provides key findings regarding the certainty of evidence, the magnitude of effect of the interventions examined, and the sum of available data on all primary and secondary outcomes. Two review authors (SE, KK) independently assessed the certainty of evidence for each outcome using the GRADE approach (<a href="./references#CD012131-bbs2-0030" title="GRADEpro GDT.Version accessed 13 January 2017. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). Any discrepancies were resolved by discussion. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012131-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012131-sec-0046"></div> <section id="CD012131-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD012131-sec-0048"> <h4 class="title">Results of the search</h4> <p>We presented the detailed results of the original search in the previously published version of this review (<a href="./references#CD012131-bbs2-0063" title="KimCH , ChenMF , ColemanAL .Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD012131. [DOI: 10.1002/14651858.CD012131.pub2]">Kim 2017</a>). Briefly, we included three studies (six reports); identified one ongoing study (two reports); and excluded four studies (four reports) from 1540 records identified by our search of the databases in December 2016. </p> <p>We performed an updated electronic database search on 17 August 2021, which yielded 337 unique records. After title and abstract screening, we retrieved nine full‐text reports for further review. We included one study (one report) and excluded eight studies (eight reports). The one newly included study was previously listed as an ongoing study (<a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). Overall, we included four studies (nine reports) and excluded 12 studies (12 reports). A study flow diagram is shown in <a href="#CD012131-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012131-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012131-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012131-sec-0049"> <h4 class="title">Included studies</h4> <p>This review includes four RCTs (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>; <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). In all trials, one eye per participant was randomized. Two trials stratified participants based on etiology groups: the groups for <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> were "post cataract," "bleb‐related," and "other" (trauma related, endogenous, post‐pars plana vitrectomy), while the groups for <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> were "postoperative" and "post‐traumatic." No studies were industry funded.  </p> <section id="CD012131-sec-0050"> <h5 class="title">Types of participants</h5> <p>We included a total of 264 participants in this review update after the exclusion of 13 participants from the "bleb‐related" group and 17 participants from the "other" group in <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>, as well as 34 participants from the "post‐traumatic" group in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>. We excluded the "bleb‐related" group because bleb‐related endophthalmitis usually occurs months to years after glaucoma surgery. All of the included studies enrolled participants with a similar clinical diagnosis of suspected bacterial endophthalmitis. Except for one participant in the "postoperative group" who had a penetrating keratoplasty prior to being diagnosed with endophthalmitis, all participants in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> had postcataract endophthalmitis. The inclusion criteria for both <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> and <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> stated that the cataract surgery must have been performed within six weeks of the onset of endophthalmitis and with the expectation that postoperative visual acuity would be 20/100 or better, <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>, or better than 20/100 (<a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> and <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> did not report a maximum time period between the date of surgery and onset of endophthalmitis. However, <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> reported the mean delay of presentation as 20.25 days when including three chronic cases, and 8.6 days when excluding chronic cases. It was not possible to exclude the participants with chronic cases from this review. All of the included studies excluded any person with suspected fungal endophthalmitis. The studies were conducted in the following countries: South Africa (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>), India (<a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>), and the Netherlands (<a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> and <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> enrolled participants who were similar in age (mean age of about 60), while <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> and <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> enrolled an older patient population (mean age of about 75 and 80, respectively). Both males and females were included in all studies. Baseline characteristics were similar between intervention groups in <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> and <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>. The other two studies did not report statistics comparing baseline characteristics between intervention groups. The overall positive culture rates were 53%, 68%, and 69% for <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>, <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>, and <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>, respectively. The positive culture rate for the postoperative group in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> was 56%. </p> </section> <section id="CD012131-sec-0051"> <h5 class="title">Types of interventions</h5> <p>All trials used intravitreous dexamethasone with intravitreous antibiotics in the steroid group. The choice of antibiotics differed by study: vancomycin and ceftazidime in <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>, vancomycin and amikacin in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>, and vancomycin and gentamicin in <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> and <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>. In each trial, the control group received the same intravitreous antibiotics as the steroid group. Participants in the control group for <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>, <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>, and <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> received antibiotics in a placebo solution, while participants in the control group in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> received intravitreous antibiotics without a placebo solution. No participants in <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> had a vitrectomy, while all participants in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> had vitrectomies. All participants with a baseline visual acuity at light perception only, and some participants with complications in <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> and <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> had vitrectomies. The trials also differed as to whether another injection of intravitreous dexamethasone and antibiotics was provided. Participants in <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> received a second injection of dexamethasone and antibiotics after 48 to 72 hours as required. Some participants in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> received another injection of intravitreous antibiotics, but no participants received additional intravitreous dexamethasone. In <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> and <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>, the injection of antibiotics and dexamethasone or placebo was repeated once in all participants three to four days later. Other additional interventions are detailed in the <a href="./references#CD012131-sec-0098" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD012131-sec-0052"> <h5 class="title">Types of outcomes</h5> <section id="CD012131-sec-0053"> <h6 class="title">Primary outcome</h6> <p>No studies reported on our primary outcome, complete resolution of endophthalmitis. However, <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> reported a somewhat similar outcome they termed "combined anatomical and functional success." This outcome was defined as the total percentage of participants with an IOP of at least 5 mmHg (i.e. anatomical success) and a BCVA of at least 6/120 (i.e. functional success). The time point for this outcome was unclear, but <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> reported that visual acuity was measured at baseline as well as one, four, and 12 weeks after surgery. Other outcomes reported by <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> involved quantitative inflammation scoring based on the clinical appearance of the cornea, anterior chamber, iris, and the vitreous. However, these outcomes were reported for postoperative and post‐traumatic participants as a whole (while combined anatomical and functional success were reported for each group separately), and were not included in the evidence for this review. </p> </section> <section id="CD012131-sec-0054"> <h6 class="title">Secondary outcomes</h6> <p>Although no study investigators reported the proportion of participants with BCVA of 20/40 (LogMAR 0.30) or better one month after the initiation of therapy as proposed in this review, <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> reported the percentage of participants in each visual outcome category and mean IOP at one year. <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> reported the percentage of participants in each of the following Snellen visual acuity groups at three months: group 1 (6/6 to 6/18), group 2 (6/24 to 6/60), group 3 (worse than 6/60). <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> reported the number of participants in each of the following Snellen visual acuity groups at three and 12 months: light perception (LP) to hand motion (HM), counting fingers (CF), 0.1 to 0.25, 0.4 to 1.0. We combined the three‐month Snellen visual acuity data by converting the percentage of participants into number of participants for each visual acuity group for <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> and regrouping the visual acuities for <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> using the cut‐offs reported in <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>. The "post cataract" group from <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> and all participants from <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> were included in the meta‐analysis. We also categorized 12‐month visual acuities from <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> into the groups used for the three‐month visual acuities (i.e. 6/6 to 6/18, 6/24 to 6/60, worse than 6/60). For both the three‐ and 12‐month visual acuity outcomes, we compared only the proportion of participants in group 1 (6/6 to 6/18) with those not in group 1 because this comparison was the most clinically useful. Although <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> reported BCVA, neither <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> nor <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> specified whether the visual acuities that they reported were 'best‐corrected.' </p> <p>While no studies reported improvement in BCVA as a proportion with a gain of 2 lines or more, <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> reported mean number of lines of improvement on a Snellen visual acuity chart for the "post‐cataract" group. For each participant, the number of lines of improvement was determined by comparing the visual acuity at three months with the visual acuity at admission. While the Snellen visual acuities at baseline, three months, and 12 months were provided for all participants in <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>, it was not possible to calculate the number of lines of improvement. Some participants had a baseline visual acuity of light perception, which does not have an equivalent visual acuity on the Snellen chart. </p> <p>Except for what was included in the "combined anatomical and functional success" outcome, no outcomes related to visual acuity or IOP were reported by <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>. The remaining three studies did not report outcomes related to IOP. </p> </section> <section id="CD012131-sec-0055"> <h6 class="title">Adverse events</h6> <p>Three studies reported adverse events in participants (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> did not report any adverse events. </p> </section> <section id="CD012131-sec-0056"> <h6 class="title">Economic data</h6> <p>No studies reported costs associated with the interventions.</p> </section> </section> </section> <section id="CD012131-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded 13 studies after full‐text review; reasons for their exclusion are provided in the <a href="./references#CD012131-sec-0099" title="">Characteristics of excluded studies</a> table. In summary, we excluded seven studies because they were not RCTs and five studies because they investigated the use of adjunctive corticosteroids for the purpose of prophylaxis. The remaining study was excluded because it examined early versus delayed intravitreal corticosteroids for the treatment of acute postoperative endophthalmitis (<a href="./references#CD012131-bbs2-0013" title="KoehrerP , BronAM , ChiquetC , ThuretG , DelboscB , BerrodJP , et al.Early versus delayed intravitreal betamethasone as an adjuvant in the treatment of presumed postoperative endophthalmitis: a randomised trial. British Journal of Ophthalmology2016;100(8):1076-80. ">Koehrer 2016</a>). </p> </section> </section> <section id="CD012131-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>A risk of bias summary assessment is shown in <a href="#CD012131-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012131-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012131-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012131-sec-0059"> <h4 class="title">Allocation</h4> <p>We assessed three trials as at low risk of bias for reporting of random sequence generation procedures (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>), and two trials at low risk of bias for allocation concealment before randomization (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). In two studies, allocation was performed by the pharmacy based on computer‐generated random sequences (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). In <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>, randomly generated assignments were placed in sealed envelopes and opened by circulating nurses just before the preparation of the intraocular solutions. However, the risk of allocation concealment was unclear because the article does not mention whether the envelopes were sequentially numbered or opaque or whether they were opened sequentially. No information on random sequence generation or allocation concealment, or both, was provided in <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>, so we assessed the risk of selection bias as unclear. </p> </section> <section id="CD012131-sec-0060"> <h4 class="title">Masking (performance bias and detection bias)</h4> <p>We assessed <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> as at low risk of performance bias because a label hid the injection assignment from the participants and the surgeon. After receiving clarification from the trial author over email that visual acuities were measured by nursing staff without any knowledge of the trial, we also assessed <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> as at low risk of detection bias. We judged <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> as having low risk of performance and detection bias because the study authors claimed that participants, study personnel, and outcome assessors were masked with the use of similar vials containing indistinguishable clear fluids. We classified the risk of performance and detection bias as unclear for the other two trials because the masking of participants and personnel administering the injection, as well as outcome assessors, was not clearly described. </p> </section> <section id="CD012131-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> reported no losses to follow‐up or adverse events, therefore we assessed the risk of attrition bias as low. We also assessed <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> as having a low risk of attrition bias because only one participant was lost to follow‐up at 12 months, and the numbers of adverse events were similar between the steroid and placebo groups. In <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>, all participants who were randomized were included in the intention‐to‐treat analysis, except for the erroneous inclusion of one participant each group; we judged this study as having low risk of attrition bias. We assessed the risk of attrition bias as unclear for <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> because four out of 62 participants in the placebo group were lost to follow‐up, and the reasons for loss to follow‐up were not reported (and were unknown to the trial author when asked by email). A modified intention‐to‐treat analysis was performed in which participants were analyzed by assigned treatment groups, but those without outcome information at three months' follow‐up were removed. </p> </section> <section id="CD012131-sec-0062"> <h4 class="title">Selective reporting</h4> <p>A clinical trial registry record was available for one study, but it was unclear if the prespecified outcomes were fully reported in the final paper (<a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). We judged this study as at unclear risk of bias. We assessed the three remaining  trials as at unclear risk of reporting bias because no trial protocols or clinical trial registry records were available to compare the planned outcomes with the reported outcomes. Furthermore, <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> reported visual acuity outcomes differently than described in the methods section of the study report. Instead of reporting visual acuity measurements at one, four, and 12 weeks postoperatively, <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> reported a combined rate of functional success (visual acuity of at least 6/120) and anatomical success (IOP of at least 5 mmHg). It was not possible to verify whether the rate of functional and anatomical success was a planned outcome because we did not have access to the original study protocol. </p> </section> <section id="CD012131-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>One study stopped enrolling participants prematurely because the manufacturer of dexamethasone withdrew it from the markets (<a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>). We assessed the risk of bias as unclear for this study. We identified no other potential risk of bias in the remaining studies (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>); none of these studies reported industry funding or other funding sources that could have introduced a conflict of interest. </p> </section> </section> <section id="CD012131-sec-0064"> <h3 class="title" id="CD012131-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD012131-tbl-0001"><b>Summary of findings 1</b> Combined steroid and antibiotic therapy compared with antibiotics alone for acute endophthalmitis after intraocular procedure</a> </p> <p>Of a total of 264 randomized participants, 259 participants were analyzed, of which 127 participants received intravitreous steroids in addition to intravitreous antibiotics and 132 participants received only intravitreous antibiotics. </p> <section id="CD012131-sec-0065"> <h4 class="title">Resolution of endophthalmitis</h4> <p>In one study, 26 (32.1%) participants in the dexamethasone group and 27 (31.4%) participants in the placebo group showed no bacterial growth in vitreous biopsy at one year (risk ratio (RR) 1.02, 95% confidence interval (CI) 0.66 to 1.60; 167 participants; <a href="./references#CD012131-fig-0005" title="">Analysis 1.1</a>) (<a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). However, it was not explicitly reported if those participants were culture‐positive or ‐negative at baseline, resulting in no analysis performed for this outcome. While no other included study reported on complete resolution of endophthalmitis, <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> reported on the rate of combined anatomical and functional success. Anatomical success was defined as IOP of at least 5 mmHg, and functional success as visual acuity of at least 6/120. Among participants with postoperative endophthalmitis, 87.5% (14 out of 16) of those who received intravitreous dexamethasone and intravitreous antibiotics achieved anatomical and functional success, compared with 81.5% (13 out of 16) of the intravitreous antibiotics‐alone group (RR 1.08, 95% CI 0.80 to 1.45; <a href="./references#CD012131-fig-0005" title="">Analysis 1.1</a>). For an unknown reason, the percentage of participants who achieved combined success in the dexamethasone group was slightly higher (i.e. 93.8%; 15 out of 16) if calculated from <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>'s Table 3 compared to the percentage reported in the results text of the study. We chose to include the percentage from the results text in the review. We graded the certainty of the evidence as very low (−1 for risk of bias, −1 for indirectness, −1 for imprecision). </p> </section> <section id="CD012131-sec-0066"> <h4 class="title">Visual acuity</h4> <p>Three studies assessed visual acuity outcomes in people with endophthalmitis after cataract surgery (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). In two studies (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>), participants who received intravitreous dexamethasone and antibiotics were more likely to have a good visual outcome (6/6 to 6/18) compared with those in the antibiotics‐alone group at three months (RR 1.95, 95% CI 1.05 to 3.60; 2 studies; N = 60; <a href="./references#CD012131-fig-0006" title="">Analysis 1.2</a>; <a href="#CD012131-fig-0003">Figure 3</a>). Two studies reported visual acuity at 12 months following treatment (<a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). The estimated risk ratio of having a good visual outcome (6/6 to 6/18, or LogMAR 0.3 or better) at 12 months was 1.12 (95% CI 0.92 to 1.37; 2 studies; N = 195; <a href="./references#CD012131-fig-0006" title="">Analysis 1.2</a>; <a href="#CD012131-fig-0003">Figure 3</a>). Although I<sup>2</sup> may represent substantial heterogeneity (I<sup>2</sup> = 67%) in this analysis, we have presented the pooled estimate because only two studies are included (i.e. low power), and the direction of effect is the same in the two studies. We assessed the certainty of evidence as low for this outcome, downgrading for risk of bias (−1) and imprecision (−1) due to wide confidence intervals. </p> <div class="figure" id="CD012131-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.2 Snellen visual acuity 6/6 to 6/18." data-id="CD012131-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.2 Snellen visual acuity 6/6 to 6/18. </p> </div> </div> </div> <p><a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> was the only study to report an outcome related to improvement in visual acuity. For participants in the postcataract group, there was no statistically significant difference in the mean number of Snellen lines of improvement at three months between those who received intravitreous dexamethasone and those who received placebo (4.1 versus 2.7, P = 0.33). <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> did not provide standard deviations (SDs) or standard errors, therefore we could not calculate the estimated mean difference and 95% CI.  </p> <p><a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> reported no visual acuity outcomes except for what was included in the combined anatomical and functional success outcome. </p> </section> <section id="CD012131-sec-0067"> <h4 class="title">Intraocular pressure</h4> <p>No study reported IOP outcome data at our prespecified time point of three months. One study showed that after 12 months of therapy, IOP changed to 13.9 mmHg (SD 4.5) from 16.3 mmHg (SD 8.7) at baseline in the dexamethasone group, and to 15.8 mmHg (SD 8.1) from 16.3 mmHg (SD 8.0) at baseline in the antibiotics‐alone group (mean difference −1.90, 95% CI −3.78 to 0.07; N = 167; <a href="./references#CD012131-fig-0007" title="">Analysis 1.3</a>) (<a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). Except for what was included in the combined anatomical and functional success outcome in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>, no other studies reported outcomes related to IOP. </p> <p>We graded the certainty of the evidence for this outcome as low (−2 for imprecision).</p> </section> <section id="CD012131-sec-0068"> <h4 class="title">Adverse events</h4> <p>Three studies reported the occurrence of adverse events, as described in <a href="#CD012131-tbl-0002">Table 1</a> (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). The total numbers of adverse events were 14 out of 111 (12.6%) for those who received dexamethasone versus 12 out of 116 (10.3%) for those who received antibiotics alone. All three retinal detachments (RDs) reported by <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> followed complicated cataract surgery and the use of intravitreous steroids. Since RDs were the only adverse events shared by the three studies, we performed a pooled analysis for this outcome with the postcataract group from <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> and all participants in <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> and <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> (<a href="#CD012131-fig-0004">Figure 4</a>). The difference in the occurrence of retinal detachment between those who received dexamethasone and those who did not was uncertain (RR 1.41, 95% CI 0.53 to 3.74; <a href="./references#CD012131-fig-0008" title="">Analysis 1.4</a>); we judged the certainty of the evidence for this outcome to be low (−1 for risk of bias, −1 for imprecision). </p> <div class="table" id="CD012131-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With dexamethasone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Antibiotics alone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Retinal detachment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/17 (17.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/14 (0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/13 (23.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/16 (25.0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/81 (2.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/86 (2.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypotony</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/13 (7.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/16 (6.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proliferative vitreoretinopathy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/13 (7.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/16 (0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seclusion of pupil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13 (0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/16 (6.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Floaters</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/81 (2.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/86 (1.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pucker</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/81 (2.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/86 (3.5%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Includes participants from the "post cataract" endophthalmitis group only. </p> </div> </div> <div class="figure" id="CD012131-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.3 Retinal detachment." data-id="CD012131-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.3 Retinal detachment. </p> </div> </div> </div> <p><a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> also reported the number of participants who underwent a secondary procedure in each intervention group. Three participants in the dexamethasone group underwent a secondary procedure (one vitrectomy and gas for RD, one vitrectomy and silicone oil for persistent inflammation and proliferative vitreoretinopathy, one vitrectomy and silicone oil for RD) compared to four participants in the placebo group (three vitrectomy and silicone oil for RD, one vitrectomy for hypotony).  </p> <p>Similarly, <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> reported the number of participants who underwent reoperations in each intervention group. Each group had six participants who underwent a vitrectomy; however, each participant had varying indications. Two participants underwent vitrectomies for floaters in the dexamethasone group compared with one participant in the placebo group. Two participants underwent vitrectomies for pucker in the dexamethasone group compared with three participants in the placebo group. Lastly, each group had two participants who underwent vitrectomies for RD. </p> <p><a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a> did not report any adverse events. </p> </section> <section id="CD012131-sec-0069"> <h4 class="title">Economic data</h4> <p>No trial reported costs associated with the interventions.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012131-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012131-sec-0070"></div> <section id="CD012131-sec-0071"> <h3 class="title" id="CD012131-sec-0071">Summary of main results</h3> <p>In this review, we have presented the results of four RCTs that compared the effects of adjunctive steroid therapy versus antibiotics alone in people with suspected bacterial endophthalmitis after an intraocular procedure. All studies used intravitreous dexamethasone for adjunctive steroid therapy and a combination of intravitreous antibiotics with gram‐positive and gram‐negative bacterial coverage for the antibiotic therapy. Overall, the included trials provided insufficient evidence to either support or refute the use of adjunctive steroids for the treatment of postoperative endophthalmitis (<a href="./full#CD012131-tbl-0001">summary of findings Table 1</a>). None of the included studies reported the primary outcome of complete resolution of endophthalmitis as defined in our protocol. One study investigated the effect of adjunctive steroid therapy on the rate of combined functional and anatomical success (as defined by visual acuity and IOP parameters) compared with antibiotics alone, and found no evidence of a difference between groups (<a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>). A pooled analysis of two studies revealed that adjunctive dexamethasone resulted in a good visual outcome (i.e. Snellen visual acuity of 6/6 to 6/18) at three months compared with antibiotics alone (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>). Conversely, there was little to no difference between participants who received adjunctive dexamethasone and those who received antibiotics alone in achieving a good visual outcome (visual acuity of 6/6 to 6/18, or LogMAR 0.3 or better) at 12 months (<a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). One study reported no difference in visual acuity improvement from baseline between the participants treated with versus those treated without steroids (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>). Although one study stratified causative organisms for endophthalmitis between the two intervention groups at one year, the effect of the interventions could not be analyzed because their baseline biopsy results were not provided. Only one study examined IOP, with results suggesting a slight reduction in IOP after 12 months with the use of adjunctive dexamethasone compared with antibiotics alone (<a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). Three studies reported adverse events; the only adverse event shared between the studies was retinal detachment (<a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>; <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>; <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>). The effect of adjunctive steroid therapy on the occurrence of retinal detachment was uncertain. No study investigated costs associated with the interventions, therefore this outcome remains unknown.  </p> </section> <section id="CD012131-sec-0072"> <h3 class="title" id="CD012131-sec-0072">Overall completeness and applicability of evidence</h3> <p>By expanding the inclusion criteria of this review to include participants with acute endophthalmitis after any type of intraocular procedure, we hoped that we would find trials that examined the treatment of endophthalmitis following a variety of intraocular procedures. However, almost all of the included trials reported outcomes for participants who were diagnosed with endophthalmitis after cataract surgery. Also, none of the included studies examined the effect of adjunctive steroid therapy by causative organism. We were therefore unable to address whether adjunctive steroids are useful in certain clinical settings (e.g. specific procedures or causative organisms). </p> <p>It should be noted that there were some differences in treatment regimens between the different studies, as well as what is considered current practice, which may limit the applicability of the evidence. Currently, a vitrectomy is recommended as soon as endophthalmitis is suspected and prior to intravitreous antibiotics for patients with a presenting visual acuity of light perception only (<a href="./references#CD012131-bbs2-0017" title="BarryP , CordovésL , GardnerS .ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. www.escrs.org/downloads/Endophthalmitis-Guidelines.pdf (accessed 23 February 2016).">Barry 2013</a>). Barry and colleagues also favor a vitrectomy for certain cases of acute endophthalmitis even if the presenting visual acuity is better than light perception (<a href="./references#CD012131-bbs2-0017" title="BarryP , CordovésL , GardnerS .ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. www.escrs.org/downloads/Endophthalmitis-Guidelines.pdf (accessed 23 February 2016).">Barry 2013</a>). If the patient does not improve within the first 24 to 48 hours, a vitrectomy would usually be considered (if not performed already), or a partial vitrectomy would be expanded to a full vitrectomy (<a href="./references#CD012131-bbs2-0017" title="BarryP , CordovésL , GardnerS .ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. www.escrs.org/downloads/Endophthalmitis-Guidelines.pdf (accessed 23 February 2016).">Barry 2013</a>). However, a vitrectomy was performed in the appropriate set of participants in <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> and <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>. All participants had a vitrectomy prior to intravitreous injection in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>, and no participants had a vitrectomy in <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>. There were also differences in the choice of intravitreous antibiotics. All studies used vancomycin, but the second antibiotic used was ceftazidime in <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a>, amikacin in <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>, and gentamicin in <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> and <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>. Current guidelines recommend using vancomycin and ceftazidime or, rarely, amikacin. Despite their synergistic effects against gram‐positive bacteria when used with vancomycin, aminoglycosides, including amikacin and gentamicin, are less frequently used because of their risk for retinal toxicity. Although gentamicin also provides gram‐negative (including <i>Pseudomonas</i>) coverage, the use of gentamicin could make these two studies less applicable to current practice than the other two studies. Also, the variability in treatment regimen following the additional injection is less than ideal. There are no guidelines on whether to give a second steroid injection, but it is recommended that a second injection of intravitreous antibiotics (antibiotic choice dependent on culture results) be considered in 24 to 48 hours if there is no improvement (<a href="./references#CD012131-bbs2-0017" title="BarryP , CordovésL , GardnerS .ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. www.escrs.org/downloads/Endophthalmitis-Guidelines.pdf (accessed 23 February 2016).">Barry 2013</a>). A repeat intravitreous antibiotic injection was only given when necessary in <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> and <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>, while all participants had a repeat injection three to four days later in <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> and <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>.  </p> <p>Inconsistency in the types of outcomes reported and follow‐up intervals made it difficult to combine the studies. Unfortunately, there is no standard way of quantifying resolution or successful management of endophthalmitis. <a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>'s measure of combined anatomical and functional success may be appropriate in a research setting, but may not be useful for determining whether treatment is successful in a clinical setting. Other potential ways of quantifying success are by clinical examination and patient‐reported eye pain (or other quality of life measures). With regard to visual acuity outcomes, we performed pooled analysis on the proportion of participants in each of the Snellen visual acuity groups (as defined by <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> or <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>) at three and 12 months. The evidence regarding visual acuity would have been more complete if visual acuity outcomes at additional time intervals had been reported and shared among studies. Had we been able to examine how visual acuity changed over time between the two intervention groups, we would have a better understanding of whether adjunctive steroid therapy is harmful or beneficial at certain points in the recovery process. </p> </section> <section id="CD012131-sec-0073"> <h3 class="title" id="CD012131-sec-0073">Quality of the evidence</h3> <p>We found two studies at an overall low risk of bias, <a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a> and <a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a>, while the other two studies had some methodological limitations (<a href="./references#CD012131-bbs2-0002" title="DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Dexamethasone in endophthalmitis treatment trial. Results of a pilot study. Investigative Ophthalmology and Visual Science1997;38:ARVO E-Abstract 2234. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Dexamethasone in endophthalmitis treatment trial. A pilot study. American Academy of Ophthalmology Annual Meeting; 1996 Oct 30; Chicago (IL). San Francisco (CA): American Academy of Ophthalmology, 1996:125. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ . In:Intravitreal dexamethasone in exogenous bacterial endophthalmitis. A prospective randomized trial. American Academy of Ophthalmology Annual Meeting; 1995 Oct 24–27; Orlando (FL). San Francisco (CA): American Academy of Ophthalmology, 1995. DasT , JalaliS , GothwalVK , SharmaS , NaduvilathTJ .Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. British Journal of Ophthalmology1999;83(9):1050-5. ">Das 1999</a>; <a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a>). We considered the evidence for the effect of adjunctive steroid therapy on combined anatomical and functional success to be of very low certainty, downgrading for unclear risk of bias for most outcomes, indirectness of outcome, and imprecision of results with uncertainty in the direction of the true effect. We graded the certainty of the evidence as low for the proportion of participants with visual acuity of 6/6 to 6/18, or LogMAR 0.3 or better, at three and 12 months due to unclear risk of bias and imprecision. We judged the certainty of the evidence for intraocular pressure as low due to imprecision of results. Lastly, we graded the certainty of the evidence for the occurrence of retinal detachment as low due to unclear risk of bias and imprecision of results. </p> </section> <section id="CD012131-sec-0074"> <h3 class="title" id="CD012131-sec-0074">Potential biases in the review process</h3> <p>We did not identify any specific biases. It is likely that all relevant studies have been included in this review, as we used a highly sensitive strategy to search bibliographic databases, clinical trial databases, and reference lists of included studies. Also, two review authors performed major steps of the review process independently in order to minimize bias and errors. </p> </section> <section id="CD012131-sec-0075"> <h3 class="title" id="CD012131-sec-0075">Agreements and disagreements with other studies or reviews</h3> <p>While only four RCTs have compared adjunctive steroid therapy with antibiotics alone for the treatment of acute postoperative endophthalmitis, several non‐randomized studies have studied this comparison. Most studies found that the use of intravitreous steroids had no significant effect on final visual outcome (<a href="./references#CD012131-bbs2-0024" title="DevS , HanDP , MielerWF , Gonzalez-VivasR , PulidoJS , MittraRA , et al.The role of intravitreal dexamethasone as an adjunct in the management of postoperative bacterial endophthalmitis. EVRS Educational Electronic Journal2005;1(5):10-7.">Dev 2005</a>; <a href="./references#CD012131-bbs2-0027" title="EifrigCW , ScottIU , Flynn HW Jr, MillerD .Endophthalmitis caused by Pseudomonas aeruginosa . Ophthalmology2003;110(9):1714-7.">Eifrig 2003</a>; <a href="./references#CD012131-bbs2-0031" title="HallEF , ScottGR , MuschDC , ZacksDN .Adjunctive intravitreal dexamethasone in the treatment of acute endophthalmitis following cataract surgery. Clinical Ophthalmology2008;2(1):139-45.">Hall 2008</a>; <a href="./references#CD012131-bbs2-0048" title="MillerJJ , ScottIU , Flynn HW Jr, SmiddyWE , CoreyRP , MillerD .Endophthalmitis caused by Streptococcus pneumoniae . American Journal of Ophthalmology2004;138(2):231-6.">Miller 2004</a>; <a href="./references#CD012131-bbs2-0052" title="PijlBJ , TheelenT , TilanusMA , RentenaarR , CramaN .Acute endophthalmitis after cataract surgery: 250 consecutive cases treated at a tertiary referral center in the Netherlands. American Journal of Ophthalmology2010;149(3):482-7.">Pijl 2010</a>). Due to the retrospective nature of these studies, there was a wide range in the follow‐up periods within and among studies, ranging from months to years. Three studies included only patients with postcataract endophthalmitis (<a href="./references#CD012131-bbs2-0024" title="DevS , HanDP , MielerWF , Gonzalez-VivasR , PulidoJS , MittraRA , et al.The role of intravitreal dexamethasone as an adjunct in the management of postoperative bacterial endophthalmitis. EVRS Educational Electronic Journal2005;1(5):10-7.">Dev 2005</a>; <a href="./references#CD012131-bbs2-0031" title="HallEF , ScottGR , MuschDC , ZacksDN .Adjunctive intravitreal dexamethasone in the treatment of acute endophthalmitis following cataract surgery. Clinical Ophthalmology2008;2(1):139-45.">Hall 2008</a>; <a href="./references#CD012131-bbs2-0052" title="PijlBJ , TheelenT , TilanusMA , RentenaarR , CramaN .Acute endophthalmitis after cataract surgery: 250 consecutive cases treated at a tertiary referral center in the Netherlands. American Journal of Ophthalmology2010;149(3):482-7.">Pijl 2010</a>), while the other two studies examined those with endophthalmitis caused by a specific organism regardless of etiology: <i>Streptococcus pneumoniae</i> in <a href="./references#CD012131-bbs2-0048" title="MillerJJ , ScottIU , Flynn HW Jr, SmiddyWE , CoreyRP , MillerD .Endophthalmitis caused by Streptococcus pneumoniae . American Journal of Ophthalmology2004;138(2):231-6.">Miller 2004</a> and <i>Pseudomonas aeruginosa</i> in <a href="./references#CD012131-bbs2-0027" title="EifrigCW , ScottIU , Flynn HW Jr, MillerD .Endophthalmitis caused by Pseudomonas aeruginosa . Ophthalmology2003;110(9):1714-7.">Eifrig 2003</a>. The one study that showed a harmful effect of adjunctive steroid therapy was <a href="./references#CD012131-bbs2-0057" title="ShahGK , SteinJD , SharmaS , SivalingamA , BensonWE , RegilloCD .Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology2000;107(3):486-9.">Shah 2000</a>, which found that administering adjunctive steroids in participants with postcataract endophthalmitis resulted in a significant worsening of visual acuity. This negative effect was seen when comparing mean visual acuities at one, three, and six months, as well as comparing the percentage of participants with a 3‐line improvement by one and three months. The <a href="./references#CD012131-bbs2-0057" title="ShahGK , SteinJD , SharmaS , SivalingamA , BensonWE , RegilloCD .Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology2000;107(3):486-9.">Shah 2000</a> study investigators proposed steroid‐induced toxicity or blunting of the immune response, or both, as possible reasons for their findings. In contrast, one small retrospective case series on culture‐positive <i>Staphylococcus aureus</i> endophthalmitis (note: 26% of participants had non‐acute postoperative endophthalmitis) showed that the addition of intravitreous dexamethasone to intravitreous antibiotics had a significantly beneficial effect on final visual outcome (<a href="./references#CD012131-bbs2-0047" title="MaoLK , Flynn HW Jr, MillerD , PflugfelderSC .Endophthalmitis caused by Staphylococcus aureus . American Journal of Ophthalmology1993;116(5):584-9.">Mao 1993</a>). Similar to our study, a significant effect was found when examining the proportion with good visual outcome (i.e. visual acuity of 20/50 or better) at last follow‐up time point (mean: 13 months, range: one month to 4.5 years). Another study that observed a beneficial effect of adjunctive steroids examined the use of systemic and topical steroids (<a href="./references#CD012131-bbs2-0040" title="KoulS , PhilipsonBT , PhilipsonA .Visual outcome of endophthalmitis in Sweden. Acta Ophthalmologica1989;67(5):504-9.">Koul 1989</a>), unlike our review. This retrospective, multicenter study in Sweden reported that participants treated with a combination of topical and systemic steroids in conjunction with intravitreous antibiotics had better final visual acuities than those treated with no steroids or only topical steroids. Only a few studies compared the occurrence of adverse events. <a href="./references#CD012131-bbs2-0024" title="DevS , HanDP , MielerWF , Gonzalez-VivasR , PulidoJS , MittraRA , et al.The role of intravitreal dexamethasone as an adjunct in the management of postoperative bacterial endophthalmitis. EVRS Educational Electronic Journal2005;1(5):10-7.">Dev 2005</a> reported no difference in the need for a second procedure to manage endophthalmitis and the occurrence of late postoperative complications, while <a href="./references#CD012131-bbs2-0027" title="EifrigCW , ScottIU , Flynn HW Jr, MillerD .Endophthalmitis caused by Pseudomonas aeruginosa . Ophthalmology2003;110(9):1714-7.">Eifrig 2003</a> reported no difference in the need for enucleation or evisceration. </p> <p>More recently, <a href="./references#CD012131-bbs2-0055" title="RobbinsCB , MaJ , FengHL , FekratS .Clinical decision making and visual outcomes in endophthalmitis treated with systemic corticosteroids. Ophthalmology Retina2020;4(11):1103-8.">Robbins 2020</a> performed a retrospective, non‐randomized comparative study in which they evaluated visual outcomes in patients with endophthalmitis who were treated with or without systemic corticosteroid therapy. Investigators found that in 133 eyes with endophthalmitis, 33 (25%) received oral steroids (and 32 of these eyes also received topical steroids). Oral steroid use was associated with an improvement in visual acuity of 3 lines or more after endophthalmitis and a greater improvement comparing visual acuity at presentation to six‐month follow‐up. However, in a retrospective chart review of 63 eyes with endophthalmitis, <a href="./references#CD012131-bbs2-0049" title="MoisseievE , AbbassiS , ParkSS .Intravitreal dexamethasone in the management of acute endophthalmitis: a comparative retrospective study. European Journal of Ophthalmology2017;27(1):67-73.">Moisseiev 2017</a> found similar improvements in mean visual acuity in the 19 eyes (30%) that received intravitreal antibiotics and dexamethasone versus the eyes that received intravitreal antibiotics alone. Given the heterogeneity of even more recent results and innovations in intraocular surgery techniques and new antibiotics, <a href="./references#CD012131-bbs2-0059" title="SolimanMK , GiniG , KuhnF , IrosM , ParoliniB , OzdekS , et al.International practice patterns for the management of acute postsurgical and postintravitreal injection endophthalmitis: European Vitreo-Retinal Society Endophthalmitis Study Report 1. Ophthalmology Retina2019;3(6):461-7.">Soliman 2019</a> was interested in evaluating current treatment patterns for endophthalmitis. In their multicenter study describing international practice patterns, <a href="./references#CD012131-bbs2-0059" title="SolimanMK , GiniG , KuhnF , IrosM , ParoliniB , OzdekS , et al.International practice patterns for the management of acute postsurgical and postintravitreal injection endophthalmitis: European Vitreo-Retinal Society Endophthalmitis Study Report 1. Ophthalmology Retina2019;3(6):461-7.">Soliman 2019</a> found that in 237 eyes diagnosed with acute endophthalmitis after intraocular surgery or intravitreal injections, all received intravitreal antibiotics on the day of presentation, but only a minority received adjunctive steroid therapies, with 25.3% receiving intravitreal steroids and 21.9% receiving systemic steroids.  </p> <p>In a narrative review of the literature, <a href="./references#CD012131-bbs2-0053" title="RahmaniS , EliottD .Postoperative endophthalmitis: a review of risk factors, prophylaxis, incidence, microbiology, treatment, and outcomes. Seminars in Ophthalmology2018;33(1):95-101.">Rahmani 2018</a> came to similar conclusions as those of this review, noting that limited small studies have not shown improvement in long‐term visual outcomes with the use of intravitreal steroids. Furthermore, <a href="./references#CD012131-bbs2-0053" title="RahmaniS , EliottD .Postoperative endophthalmitis: a review of risk factors, prophylaxis, incidence, microbiology, treatment, and outcomes. Seminars in Ophthalmology2018;33(1):95-101.">Rahmani 2018</a> pointed out that although adjunctive steroids are commonly used at the time of diagnosis for more severe cases of endophthalmitis, surgeons should exercise caution and consider the potential for inadequate first‐line antibiotic coverage, and think about waiting until the pathogen and drug sensitivities are identified before using intravitreal steroids. </p> <p>Considering the paucity of data and heterogeneity of the results, it is not possible to conclude whether intravitreous dexamethasone is beneficial or harmful in the treatment of acute endophthalmitis after intraocular procedure from these studies. A recent review concluded that since most of the current literature does not show an effect of adjunctive steroid therapy, and <a href="./references#CD012131-bbs2-0057" title="ShahGK , SteinJD , SharmaS , SivalingamA , BensonWE , RegilloCD .Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology2000;107(3):486-9.">Shah 2000</a> showed a detrimental effect, the routine use of adjunctive intravitreous steroids for acute endophthalmitis is not supported at this time (<a href="./references#CD012131-bbs2-0019" title="BuiDK , CarvounisPE .Evidence for and against intravitreous corticosteroids in addition to intravitreous antibiotics for acute endophthalmitis. International Ophthalmology Clinics2014;54(2):215-24.">Bui 2014</a>). We agree with <a href="./references#CD012131-bbs2-0019" title="BuiDK , CarvounisPE .Evidence for and against intravitreous corticosteroids in addition to intravitreous antibiotics for acute endophthalmitis. International Ophthalmology Clinics2014;54(2):215-24.">Bui 2014</a> that RCTs at low risk of bias and with adequate power should be completed to clarify whether adjunctive steroid therapy may be helpful in certain clinical settings and should be avoided in others. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012131-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/urn:x-wiley:14651858:media:CD012131:CD012131-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012131-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_t/tCD012131-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012131-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/urn:x-wiley:14651858:media:CD012131:CD012131-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012131-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_t/tCD012131-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012131-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/urn:x-wiley:14651858:media:CD012131:CD012131-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.2 Snellen visual acuity 6/6 to 6/18." data-id="CD012131-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_t/tCD012131-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.2 Snellen visual acuity 6/6 to 6/18. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012131-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/urn:x-wiley:14651858:media:CD012131:CD012131-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.3 Retinal detachment." data-id="CD012131-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_t/tCD012131-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.3 Retinal detachment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012131-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/urn:x-wiley:14651858:media:CD012131:CD012131-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 1: Resolution of endophthalmitis" data-id="CD012131-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_t/tCD012131-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 1: Resolution of endophthalmitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/references#CD012131-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012131-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/urn:x-wiley:14651858:media:CD012131:CD012131-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 2: Visual acuity" data-id="CD012131-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_t/tCD012131-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 2: Visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/references#CD012131-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012131-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/urn:x-wiley:14651858:media:CD012131:CD012131-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 3: Intraocular pressure (IOP)" data-id="CD012131-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_t/tCD012131-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 3: Intraocular pressure (IOP) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/references#CD012131-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012131-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/urn:x-wiley:14651858:media:CD012131:CD012131-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 4: Retinal detachment" data-id="CD012131-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_t/tCD012131-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 4: Retinal detachment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/references#CD012131-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/media/CDSR/CD012131/image_n/nCD012131-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012131-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Combined steroid and antibiotic therapy compared with antibiotics alone for acute endophthalmitis after intraocular procedure</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combined steroid and antibiotic therapy compared with antibiotics alone for acute endophthalmitis after intraocular procedure</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection) </p> <p><b>Settings:</b> ophthalmology clinic or hospital </p> <p><b>Intervention:</b> steroids plus antibiotics </p> <p><b>Comparison:</b> antibiotics alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes*</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks** (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>A<b>ntibiotics alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Combined steroid and antibiotic therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete resolution of endophthalmitis</b> </p> <p>at 3 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>813 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>878 per 1000</b><br/>(650 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b><br/>(0.80 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessed as combined anatomical and functional success, where anatomical success was defined as IOP of at least 5 mmHg, and functional success was defined as visual acuity of at least 6/120 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Visual acuity 6/6 to 6/18</b> </p> <p>at 3 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>585 per 1000</b><br/>(315 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.95</b><br/>(1.05 to 3.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Visual acuity 6/6 to 6/18, or LogMAR 0.3 or better</b> </p> <p>at 12 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>627 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>710 per 1000</b> </p> <p>(704 to 750)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b><br/>(0.92 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in visual acuity</b> </p> <p>at 3 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigators of 1 study reported improvement in visual acuity, but the effect of adjunctive steroid therapy could not be estimated because the study investigators did not provide standard deviations or standard errors. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intraocular pressure</b> </p> <p>at 12 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IOP was 15.8 mmHg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IOP was on average <b>1.90 lower</b> (95% CI −3.78 to 0.07). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>－</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167 <br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Low<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>at 3 to 12 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b><br/>(25 to 231) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.41</b><br/>(0.53 to 3.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>1,2</sup> </b><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data are for <b>retinal detachment</b>. Other reported adverse events included hypotony (2/29 participants), proliferative vitreoretinopathy (1/29 participants), seclusion of pupil (1/29 participants), floaters (3/167 participants), and pucker (5/167 participants). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Costs associated with the interventions</b> </p> <p>at 3 months' follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The primary follow‐up time point for the review was 1 month; however, none of the included trials reported outcomes at this time point. Data are presented for the follow‐up time point for which data were available.<br/>**The basis for the <b>assumed risk</b> was the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded (−1) for unclear risk of bias in the trials.<br/><sup>2</sup>Downgraded (−1) for imprecision (wide confidence interval).<br/><sup>3</sup>Downgraded (−1) for indirectness of the outcome definition.<br/><sup>4</sup>Downgraded (−2) for imprecision (very wide confidence interval). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Combined steroid and antibiotic therapy compared with antibiotics alone for acute endophthalmitis after intraocular procedure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012131-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With dexamethasone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Antibiotics alone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Retinal detachment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0001" title="AlbrechtE , RichardsJC , PollockT , CookC , MyersL .Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. British Journal of Ophthalmology2011;95(10):1385-8. ">Albrecht 2011</a><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/17 (17.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/14 (0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/13 (23.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/16 (25.0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/81 (2.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/86 (2.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypotony</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/13 (7.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/16 (6.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proliferative vitreoretinopathy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/13 (7.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/16 (0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seclusion of pupil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0003" title="GanIM , UgaharyLC , vanDisselJT , FeronE , PeperkampE , VeckeneerM , et al.Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefe's Archive for Clinical and Experimental Ophthalmology2005;243(12):1200-5. ">Gan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13 (0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/16 (6.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Floaters</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/81 (2.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/86 (1.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pucker</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012131-bbs2-0004" title="LindstedtEW , BennebroekCA , WerfDJ , VeckeneerM , NorelAO , NielsenCC , et al.A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(10):1631-7. ManningS , UgaharyLC , LindstedtEW , WubbelsRJ , vanDisselJT , JansenJTG , et al.A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmologica2018;96(4):348‐55. NTR189.Intravitreal dexamethason treatment of bacterial endophthalmitis. www.trialregister.nl/trial/154 (first received 23 August 2005). vanMeursJ .Re: Inquiry about your study &quot;A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics&quot;. Email to: S Ng 11 November 2021. ">Manning 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/81 (2.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/86 (3.5%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Includes participants from the "post cataract" endophthalmitis group only. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/full#CD012131-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012131-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adjunctive intravitreal dexamethasone versus antibiotics alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Resolution of endophthalmitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.05, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.92, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Intraocular pressure (IOP) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Retinal detachment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.53, 3.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adjunctive intravitreal dexamethasone versus antibiotics alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012131.pub3/references#CD012131-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012131.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012131-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012131-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012131-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012131-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012131-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD012131-note-0007">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012131-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012131-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012131\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012131\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012131\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012131\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012131\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012131.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012131.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012131.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012131.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012131.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725248770"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012131.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725248774"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012131.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e769ecbb6936e',t:'MTc0MDcyNTI0OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 